What is Vor Biopharma's gain/loss on asset sales?

Vor Biopharma (VOR) reported gain/loss on asset sales of $0 in Q1 2026.

How has Vor Biopharma's gain/loss on asset sales changed year-over-year?

Vor Biopharma's gain/loss on asset sales increased by 100.0% year-over-year, from -$1K to $0.

Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.

Iovance Biotherapeutics, Inc.IOVA

-$28K+36.4%

ImmunomeIMNM

-$79K—

Operating income-$35.2M-5.6%

Net income-$219.6M-576%

EPS (diluted)-$5.11+1.9%

Cash & equivalents$169.9M+239%

Total debt$2.9M-90.5%

Total equity-$150.4M-328%

Total assets$506.7M+364%

Operating cash flow-$38.2M-23.1%

CapEx$48.0K-79.2%

Free cash flow-$38.3M-22.4%

Market cap$784.61M+2,594%

Enterprise value$617.68M+5,866%

Return on equity-125.4%+671pp

Debt / equity0.5×+0.2×

Current ratio31.1×+27.3×

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Vor Biopharma's gain/loss on asset sales?: Vor Biopharma (VOR) reported gain/loss on asset sales of $0 in Q1 2026.
How has Vor Biopharma's gain/loss on asset sales changed year-over-year?: Vor Biopharma's gain/loss on asset sales increased by 100.0% year-over-year, from -$1K to $0.
What does gain/loss on asset sales mean?: Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.